CDK4/6 Inhibitors in Early-Stage HR+/HER2- Breast Cancer: Individualizing Therapeutic Decisions to Improve Patient Outcomes

Learn how global experts are leveraging the latest data on CDK4/6 inhibitors in patients with HR+/HER2- EBC. Watch the on-demand webcast from the live webinar download the slides and listen to the podcast featuring expert reviews of the most important data on early breast cancer from ESMO Breast 2021.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Lilly